Catherine Martini, Anthony Latronica, Sadie Salmone, Angela Murrin, Nathan Haulthus, Kaitlynn Alleman, Elizabeth Conley, Kathleen Mcaslin, Laura Ann Bute, Molly Herr, Sofia Sacchetti, Karishma Gangwani
Download Project (5.9 MB)
Glioma is a lethal brain cancer, and current treatment strategies have limited effects by extending life only by a few months. Thus, efforts should be made to discover better inhibitors of glioma growth. Ideally such inhibitors will suppress the progression of glioma by (a) inhibiting the underlying molecular pathways activated in glioma, or (b) prevent rapid proliferation of the glia and other cells that encompass the glioma tumor. We have developed a glioma model by co-activating PI3K and Ras/MAPK specifically in the Drosophila CNS glia. The Drosophila glioma cause the larval brain to appear enlarged due to rapid increase in the stem cells and their glial and neural progeny. These tumors cause the larvae to enter a prolonged larval phase, and eventually kill the organism. We are conducting a chemical screen using Tyrosine kinase inhibitors (Selleck Biochem.) in which we feed early third instar (72h old) larvae 10 or 300uM chemicals in DMSO and then see effects on glioma growth, and survival in mature third instar stage (120h old). Using these metrics, here we present data from our screen on B1-B11 of the library. Once we identify potential glioma inhibitors in the primary screens, we will validate them in secondary screens.
Primary Advisor's Department
Stander Symposium Posters, College of Arts and Sciences
"Possible pharmacologic glioma treatment in Drosophila model" (2021). Stander Symposium Projects. 2386.